JP2024543147A5 - - Google Patents

Info

Publication number
JP2024543147A5
JP2024543147A5 JP2024531227A JP2024531227A JP2024543147A5 JP 2024543147 A5 JP2024543147 A5 JP 2024543147A5 JP 2024531227 A JP2024531227 A JP 2024531227A JP 2024531227 A JP2024531227 A JP 2024531227A JP 2024543147 A5 JP2024543147 A5 JP 2024543147A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543147A (ja
Filing date
Publication date
Priority claimed from PCT/JP2021/043459 external-priority patent/WO2023095305A1/en
Application filed filed Critical
Publication of JP2024543147A publication Critical patent/JP2024543147A/ja
Publication of JP2024543147A5 publication Critical patent/JP2024543147A5/ja
Pending legal-status Critical Current

Links

JP2024531227A 2021-11-26 2022-10-25 中枢神経系(cns)の脱髄疾患のサトラリズマブによる治療 Pending JP2024543147A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/JP2021/043459 WO2023095305A1 (en) 2021-11-26 2021-11-26 Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
JPPCT/JP2021/043459 2021-11-26
PCT/JP2022/039605 WO2023095510A1 (en) 2021-11-26 2022-10-25 Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab

Publications (2)

Publication Number Publication Date
JP2024543147A JP2024543147A (ja) 2024-11-19
JP2024543147A5 true JP2024543147A5 (cg-RX-API-DMAC7.html) 2025-10-30

Family

ID=86539186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531227A Pending JP2024543147A (ja) 2021-11-26 2022-10-25 中枢神経系(cns)の脱髄疾患のサトラリズマブによる治療

Country Status (10)

Country Link
US (1) US20250034265A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543147A (cg-RX-API-DMAC7.html)
KR (1) KR20240107372A (cg-RX-API-DMAC7.html)
CN (1) CN118591389A (cg-RX-API-DMAC7.html)
AU (1) AU2022398430A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238940A1 (cg-RX-API-DMAC7.html)
IL (1) IL313058A (cg-RX-API-DMAC7.html)
MX (1) MX2024006393A (cg-RX-API-DMAC7.html)
TW (1) TW202330030A (cg-RX-API-DMAC7.html)
WO (3) WO2023095305A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010065116A2 (en) 2008-12-02 2010-06-10 The Trustees Of The University Of Pennsylvania The use of il-27-p28 to antagonize il-6 mediated signaling
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途

Similar Documents

Publication Publication Date Title
Bruijstens et al. EU paediatric MOG consortium consensus: Part 5–Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders
CN114173816A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
JP2023551559A5 (cg-RX-API-DMAC7.html)
JP2024511970A5 (cg-RX-API-DMAC7.html)
JP2023545084A5 (cg-RX-API-DMAC7.html)
Marzano et al. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab)
van der Meché et al. The current place of high‐dose immunoglobulins in the treatment of neuromuscular disorders
TW202337495A (zh) 用satralizumab治療自體免疫腦炎
JP2025512785A5 (cg-RX-API-DMAC7.html)
JP2021515039A5 (cg-RX-API-DMAC7.html)
JP2024540435A5 (cg-RX-API-DMAC7.html)
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
RU2011117293A (ru) Композиция для лечения заболевания
JP2024521105A5 (cg-RX-API-DMAC7.html)
JP2023546504A5 (cg-RX-API-DMAC7.html)
Tenembaum Therapy of multiple sclerosis in children and adolescents
Wolf et al. Drug safety in thyroid eye disease–a systematic review
CN119894516A (zh) 用于治疗晚期实体瘤的组合物和方法
JP2023551519A5 (cg-RX-API-DMAC7.html)
AU2019237774B2 (en) Anti-VEGFR-2 antibody
JP2025526402A5 (cg-RX-API-DMAC7.html)
JP2024518410A5 (cg-RX-API-DMAC7.html)
AU2022273206A1 (en) Methods of treating dermatomyositis
Alvi et al. Post COVID anti-NMDAR encephalitis in an adolescent girl
Khim Myasthenia gravis treatment